Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

We maintain Eli Lilly’s High Uncertainty Rating ... including level of insurance coverage and pricing. Alzheimer’s drug donanemab holds the potential to become another major new drug, but ...

Nico Chen’s rating is based on a combination of factors that highlight Eli Lilly & Co’s promising ... for diabetes and weight loss, and Donanemab for Alzheimer’s disease.